Live Earnings Conference Call: Neumora Therapeutics will host a live Q1 2025 earnings call on May 12, 2025 at 4:30PM ET. Follow this link to get details and listen to Neumora Therapeutics' Q1 2025 earnings call when it goes live. Get details. Neumora Therapeutics (NMRA) Competitors $0.66 +0.02 (+3.79%) As of 05/9/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. SAGE, PGEN, ZVRA, PRTA, PRTC, SANA, ALT, ERAS, TRML, and MREOShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Sage Therapeutics (SAGE), Precigen (PGEN), Zevra Therapeutics (ZVRA), Prothena (PRTA), PureTech Health (PRTC), Sana Biotechnology (SANA), Altimmune (ALT), Erasca (ERAS), Tourmaline Bio (TRML), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Sage Therapeutics Precigen Zevra Therapeutics Prothena PureTech Health Sana Biotechnology Altimmune Erasca Tourmaline Bio Mereo BioPharma Group Neumora Therapeutics (NASDAQ:NMRA) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment. Does the MarketBeat Community believe in NMRA or SAGE? Sage Therapeutics received 604 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 76.32% of users gave Neumora Therapeutics an outperform vote while only 64.99% of users gave Sage Therapeutics an outperform vote. CompanyUnderperformOutperformNeumora TherapeuticsOutperform Votes2976.32% Underperform Votes923.68% Sage TherapeuticsOutperform Votes63364.99% Underperform Votes34135.01% Which has more volatility and risk, NMRA or SAGE? Neumora Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Does the media prefer NMRA or SAGE? In the previous week, Neumora Therapeutics had 2 more articles in the media than Sage Therapeutics. MarketBeat recorded 6 mentions for Neumora Therapeutics and 4 mentions for Sage Therapeutics. Neumora Therapeutics' average media sentiment score of 1.00 beat Sage Therapeutics' score of 0.59 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sage Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts rate NMRA or SAGE? Neumora Therapeutics presently has a consensus price target of $9.29, indicating a potential upside of 1,300.98%. Sage Therapeutics has a consensus price target of $8.81, indicating a potential upside of 34.34%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Neumora Therapeutics is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22Sage Therapeutics 2 Sell rating(s) 15 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings and valuation, NMRA or SAGE? Neumora Therapeutics has higher earnings, but lower revenue than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$235.93M-$1.53-0.43Sage Therapeutics$47.40M8.67-$400.67M-$5.80-1.13 Do institutionals and insiders believe in NMRA or SAGE? 47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by company insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is NMRA or SAGE more profitable? Neumora Therapeutics has a net margin of 0.00% compared to Sage Therapeutics' net margin of -971.50%. Sage Therapeutics' return on equity of -68.18% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -73.63% -68.97% Sage Therapeutics -971.50%-68.18%-60.84% SummaryNeumora Therapeutics beats Sage Therapeutics on 12 of the 17 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.21M$2.79B$5.33B$7.99BDividend YieldN/A1.88%5.45%4.20%P/E Ratio-0.3530.1122.6219.04Price / SalesN/A434.98393.05108.07Price / CashN/A168.6838.4134.62Price / Book0.222.996.634.32Net Income-$235.93M-$72.35M$3.23B$248.50M7 Day Performance-4.99%-5.88%-1.77%1.87%1 Year Performance-92.79%-28.05%15.45%5.28% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics3.2917 of 5 stars$0.66+3.8%$9.29+1,301.0%-92.8%$107.21MN/A-0.35108Upcoming EarningsNews CoverageSAGESage Therapeutics4.2539 of 5 stars$7.17-1.8%$8.81+22.9%-44.9%$448.99M$47.40M-1.09690PGENPrecigen3.45 of 5 stars$1.52-3.2%$7.00+360.5%+4.7%$448.65M$3.93M-2.76190Upcoming EarningsNews CoverageZVRAZevra Therapeutics2.523 of 5 stars$8.00flat$22.29+178.6%+63.3%$437.43M$23.61M-4.0620Upcoming EarningsPRTAProthena3.3326 of 5 stars$8.08-4.9%$55.00+580.7%-65.2%$434.92M$135.16M-3.51130Earnings ReportAnalyst ForecastNews CoverageHigh Trading VolumePRTCPureTech Health2.2992 of 5 stars$17.84+1.7%$45.00+152.2%-38.9%$428.50M$4.32M0.00100SANASana Biotechnology1.8786 of 5 stars$1.87-1.1%$10.80+477.5%-76.1%$421.64MN/A-1.34380Earnings ReportUpcoming EarningsGap DownALTAltimmune2.1525 of 5 stars$5.43-5.9%$20.83+283.7%-22.6%$418.19M$20,000.00-3.5050Options VolumeERASErasca2.8814 of 5 stars$1.45-8.2%$4.83+233.3%-24.9%$410.74MN/A-1.75120Upcoming EarningsTRMLTourmaline Bio2.5431 of 5 stars$15.92-2.3%$49.33+209.9%+4.1%$408.91MN/A-5.6544Earnings ReportAnalyst RevisionNews CoverageMREOMereo BioPharma Group2.1274 of 5 stars$2.55-4.5%$7.71+202.5%-20.5%$405.45M$1M-42.5040Positive News Related Companies and Tools Related Companies Sage Therapeutics Competitors Precigen Competitors Zevra Therapeutics Competitors Prothena Competitors PureTech Health Competitors Sana Biotechnology Competitors Altimmune Competitors Erasca Competitors Tourmaline Bio Competitors Mereo BioPharma Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 5/12/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA New Economic Shift – How You Can PrepareWhile everyone's focused on the Fed and interest rates... most investors are missing the real story. There'...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NMRA Stock Free NMRA Stock Alerts